CY1118801T1 - Πεπτιδια, προϊοντα συζευξης και μεθοδος για την αυξηση της ανοσογονικοτητας ενος εμβολιου - Google Patents

Πεπτιδια, προϊοντα συζευξης και μεθοδος για την αυξηση της ανοσογονικοτητας ενος εμβολιου

Info

Publication number
CY1118801T1
CY1118801T1 CY20171100217T CY171100217T CY1118801T1 CY 1118801 T1 CY1118801 T1 CY 1118801T1 CY 20171100217 T CY20171100217 T CY 20171100217T CY 171100217 T CY171100217 T CY 171100217T CY 1118801 T1 CY1118801 T1 CY 1118801T1
Authority
CY
Cyprus
Prior art keywords
vaccine
peptides
relates
coupling products
increasing immunogenicity
Prior art date
Application number
CY20171100217T
Other languages
English (en)
Inventor
Ferdinand Antonius Ossendorp
Cornelis Joseph Maria Melief
Jan Wouter Drijfhout
Original Assignee
Academisch Ziekenhuis Leiden H.O.D.N. Lumc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden H.O.D.N. Lumc filed Critical Academisch Ziekenhuis Leiden H.O.D.N. Lumc
Publication of CY1118801T1 publication Critical patent/CY1118801T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε προϊόντα σύζευξης που περιλαμβάνουν ένα πεπτίδιο τουλάχιστον 10 υπολειμμάτων αμινοξέων που περιλαμβάνουν την αλληλουχία αμινοξέων GITELKKL για την επαγωγή ισχυρών χυμικών και κυτταρικών ανοσοαποκρίσεων, όταν χορηγούνται σε υποκείμενα που έχουν αντισώματα έναντι της ανατοξίνης του τετάνου. Σε μία ενσωμάτωση η εφεύρεση αναφέρεται σε ένα προφυλακτικό και θεραπευτικό εμβόλιο και σε μία περαιτέρω ενσωμάτωση η εφεύρεση σχετίζεται με την θεραπεία ή την πρόληψη του καρκίνου ή μιας μολυσματικής ασθένειας.
CY20171100217T 2010-03-15 2017-02-16 Πεπτιδια, προϊοντα συζευξης και μεθοδος για την αυξηση της ανοσογονικοτητας ενος εμβολιου CY1118801T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10156505 2010-03-15
US31793010P 2010-03-26 2010-03-26
PCT/NL2011/050180 WO2011115483A1 (en) 2010-03-15 2011-03-15 Peptides, conjugates and method for increasing immunogenicity of a vaccine
EP11712343.0A EP2547364B1 (en) 2010-03-15 2011-03-15 Peptides, conjugates and method for increasing immunogenicity of a vaccine

Publications (1)

Publication Number Publication Date
CY1118801T1 true CY1118801T1 (el) 2018-01-10

Family

ID=43430699

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100217T CY1118801T1 (el) 2010-03-15 2017-02-16 Πεπτιδια, προϊοντα συζευξης και μεθοδος για την αυξηση της ανοσογονικοτητας ενος εμβολιου

Country Status (15)

Country Link
US (1) US9522962B2 (el)
EP (1) EP2547364B1 (el)
CN (1) CN102892431A (el)
CA (1) CA2793087C (el)
CY (1) CY1118801T1 (el)
DK (1) DK2547364T3 (el)
ES (1) ES2616258T3 (el)
HR (1) HRP20170251T1 (el)
HU (1) HUE031924T2 (el)
LT (1) LT2547364T (el)
PL (1) PL2547364T3 (el)
PT (1) PT2547364T (el)
RS (1) RS55670B1 (el)
SI (1) SI2547364T1 (el)
WO (1) WO2011115483A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014111724A1 (en) 2013-01-18 2014-07-24 London School Of Hygiene And Tropical Medicine Glycosylation method
GB201301085D0 (en) * 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
CN106456766B (zh) * 2014-03-19 2020-03-10 台湾基督长老教会马偕医疗财团法人马偕纪念医院 抗免疫原性糖肽的抗体、包含其的组合物及其用途
CN106986923B (zh) * 2017-04-10 2021-01-26 新疆农垦科学院 GnRH抗原及其在主动免疫对公牛的去势效果及肉品质影响中的应用
MX2020010621A (es) 2018-04-10 2020-10-20 Ac Immune Sa Vacunas terapeuticas anti-abeta.
AU2019315327B2 (en) * 2018-07-31 2024-05-09 Snoretox Pty Ltd Pegylated tetanus neurotoxins and treatment of hypotonia
CA3119865A1 (en) 2018-11-23 2020-05-28 Strike Pharma Ab Bi-specific conjugates
GB201917699D0 (en) 2019-12-04 2020-01-15 Ultimovacs Ab Vaccine conjugates
AU2021216611A1 (en) * 2020-02-03 2022-08-25 Snoretox Ltd Composition and method
US20240245763A9 (en) * 2020-02-06 2024-07-25 Longhorn Vaccines And Diagnostics, Llc Vaccines for the Treatment and Prevention of Zoonotic Infections
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
US20220296696A1 (en) * 2020-10-20 2022-09-22 Longhorn Vaccines And Diagnostics, Llc Immunogenic Antigens
CA3222077A1 (en) * 2021-06-09 2022-12-15 Dana Michel A conjugate
WO2024121411A1 (en) 2022-12-09 2024-06-13 Strike Pharma Ab Optimized tag moiety
WO2024126737A1 (en) 2022-12-14 2024-06-20 Ultimovacs Ab A core and a conjugate
WO2024126758A2 (en) 2022-12-14 2024-06-20 Ultimovacs Ab A nucleic acid molecule and a chimeric polypeptide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
JPH09510437A (ja) * 1993-12-28 1997-10-21 カイロン ミモトープス プロプライエトリー リミテッド Ｔ細胞エピトープ
US6372225B1 (en) * 1996-03-23 2002-04-16 The Research Foundation Of Microbial Diseases Of Osaka University Tetanus toxin functional fragment antigen and tetanus vaccine
WO1998018496A2 (en) 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
FR2806727A1 (fr) * 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
AU2002219711B8 (en) 2000-12-08 2006-03-02 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
JP2005535627A (ja) * 2002-06-25 2005-11-24 シティ・オブ・ホープ アジュバント不含ペプチド・ワクチン
US9662383B2 (en) 2007-03-26 2017-05-30 University Of Massachusetts Compositions and methods for increasing immunogenicity of glycoprotein vaccines

Also Published As

Publication number Publication date
WO2011115483A1 (en) 2011-09-22
PT2547364T (pt) 2017-02-21
ES2616258T3 (es) 2017-06-12
LT2547364T (lt) 2017-03-27
EP2547364B1 (en) 2016-12-14
CA2793087A1 (en) 2011-09-22
CA2793087C (en) 2019-07-23
SI2547364T1 (sl) 2017-05-31
US20130071428A1 (en) 2013-03-21
HRP20170251T1 (hr) 2017-04-21
RS55670B1 (sr) 2017-06-30
PL2547364T3 (pl) 2017-06-30
HUE031924T2 (en) 2017-08-28
DK2547364T3 (en) 2017-02-27
CN102892431A (zh) 2013-01-23
EP2547364A1 (en) 2013-01-23
US9522962B2 (en) 2016-12-20

Similar Documents

Publication Publication Date Title
CY1118801T1 (el) Πεπτιδια, προϊοντα συζευξης και μεθοδος για την αυξηση της ανοσογονικοτητας ενος εμβολιου
CY1122235T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενου του γαστρεντερικου και του γαστρικου καρκινου
CY1121789T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
CY1118373T1 (el) Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος
CY1120352T1 (el) Ανοσοθεραπεια βασισμενη στη 2,3 διοξυγοναση της ινδολεαμινης
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1112186T1 (el) Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ιι
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
BR112017003108A2 (pt) anticorpo ou fragmento de ligação a antígeno do mesmo, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos para produção de um anticorpo ou fragmento de ligação a antígeno, para tratamento de câncer e de uma infecção ou doença infecciosa, para detecção da presença de um peptídeo de tigit ou um fragmento do mesmo e para aumentar a atividade de uma célula imune e a atividade antitumoral de um anticorpo anti-tigit, vacina, e, uso de um anticorpo ou fragmento de ligação a antígeno
MX2010001090A (es) Nuevos epitopos inmunogenicos para inmunoterapia.
NZ604089A (en) Multivalent glycopeptide constructs and uses thereof
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
MX2013013111A (es) Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma.
CY1124950T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων, οπως του καρκινου του πνευμονα συμπεριλαμβανομενου του μμκπ
BR112019001656A2 (pt) composição, composição farmacêutica, vacina, método para induzir anticorpos em um indivíduo, método para tratar câncer em um paciente necessitando do mesmo e método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
MX2019003682A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
EA201290675A1 (ru) Вакцинные векторы и способы усиления иммунных ответов
BR112017005120A2 (pt) composição, conjugado terapêutico isolado, método para tratar câncer em um paciente necessitando do mesmo, método para induzir anticorpos em um indivíduo, composição farmacêutica e método para induzir anticorpos em um indivíduo
MX2020012913A (es) Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas.
EA201891639A1 (ru) Аминокислотные и пептидные конъюгаты и способ конъюгации
CY1119638T1 (el) Παραλλαγη gp-120 του ηiv
EA202090319A1 (ru) Пептидные конъюгаты, способ конъюгации и их использование
BR112012022059A8 (pt) Vacina de mucosa produtora de uma iga de mucosa antígenoespecífica e igg do sangue e método para produzir uma vacina de mucosa
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same